PAR · ALVAL.PA
Valbiotis S.A.
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
Loading market information…
PAR · ALPAT.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 03:23 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Plant Advanced Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Plant Advanced Technologies S.A.’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Plant Advanced Technologies S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce your exclusive, personalized Exudactive; and PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes. Plant Advanced Technologies SA was incorporated in 2005 and is headquartered in Vandœuvre-lès-Nancy, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
€0.10-€0.00 (-0.31%)
Mauna Kea Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 58.36% below the high.
€5.55+€0.05 (+0.91%)
Euromedis Groupe’s quoted price sits in the upper half of its reported 52-week range, 9.76% below the high.
€0.85+€0.01 (+1.19%)
Biosynex S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.86% below the high.
€0.14+€0.02 (+16.5%)
TME Pharma N.V.’s quoted price sits in the upper half of its reported 52-week range, 19.93% below the high.
€0.10-€0.00 (-2.44%)
AMA Corporation Plc’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
€2.20€0.00 (0.0%)
Media Lab S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
€0.40-€0.02 (-4.98%)
NFL Biosciences S.A.’s quoted price sits in the lower half of its reported 52-week range, 78.32% below the high.
